Telmisartan reduces progressive accumulation of cellular amyloid beta and phosphorylated tau with inflammatory responses in aged spontaneously hypertensive stroke resistant rat

Journal of Stroke and Cerebrovascular Diseases

Volumn 23, Issue 10, 2014, Pages 2580-2590

  Kurata, Tomoko ^a   Lukic, Violeta ^a   Kozuki, Miki ^a   Wada, Daisuke ^a   Miyazaki, Kazunori ^a   Morimoto, Nobutoshi ^a   Ohta, Yasuyuki ^a   Deguchi, Kentaro ^a   Ikeda, Yoshio ^a   Kamiya, Tatsushi ^a   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Inflammation; Spontaneously hypertensive rat; Telmisartan

Indexed keywords

AMYLOID BETA PROTEIN; CALCIUM ION; MONOCYTE CHEMOTACTIC PROTEIN 1; TAU PROTEIN; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; ACTIN BINDING PROTEIN; AIF1 PROTEIN, RAT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; CALCIUM BINDING PROTEIN; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DRUG MEGADOSE; HYPERTENSION; IMMUNOHISTOLOGY; INFLAMMATION; LOW DRUG DOSE; MALE; METABOLIC SYNDROME X; MICROGLIA; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; AGE; ANIMAL; CYTOLOGY; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; SPONTANEOUSLY HYPERTENSIVE RAT; TIME; TREATMENT OUTCOME; WISTAR RAT;

AGE FACTORS; AMYLOID BETA-PEPTIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; CALCIUM-BINDING PROTEINS; CEREBRAL CORTEX; CHEMOKINE CCL2; INFLAMMATION; MALE; MICROFILAMENT PROTEINS; MICROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; RATS; RATS, INBRED SHR; RATS, WISTAR; TAU PROTEINS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923254431     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2014.05.023     Document Type: Article

References (45)

1. Skoog I, Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res 2006; 28: 605-611.
2. Mogi M, Horiuchi M. Neurovascular coupling in cognitive impairment associated with diabetes mellitus. Circ J. 75: 1042-1048.
3. Kuller LH, Lopez OL, Jagust WJ, et al. Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology 2005; 64: 1548-1552.
4. Hayden KM, Zandi PP, Lyketsos CG, et al. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord 2006; 20: 93-100.
5. Alexander RW. Leukocyte and endothelial angiotensin II type 1 receptors and microvascular thrombotic and inflammatory responses to hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006; 26: 240-241.
6. Carnevale D, Mascio G, D'Andrea I, et al. Hypertension induces brain b-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension; 60: 188-197.
7. Korenova M, Zilka N, Stozicka Z, et al. NeuroScale, the battery of behavioral tests with novel scoring system for phenotyping of transgenic rat model of tauopathy. J Neurosci Methods 2009; 177: 108-114.
8. Sabbatini M, Catalani A, Consoli C, et al. The hippocampus in spontaneously hypertensive rats: an animal model of vascular dementia? Mech Ageing Dev 2002; 123: 547-559.
9. Yamori Y, Horie R, Sato M, et al. Hypertension as an important factor for cerebrovascular atherogenesis in rats. Stroke 1976; 7: 120-125.
10. Iritani N, Fukuda E, Nara Y, et al. Lipid metabolism in spontaneously hypertensive rats (SHR). Atherosclerosis 1977; 28: 217-222.
11. Pravenec M, Landa V, Zidek V, et al. Transgenic expression of CD36 in the spontaneously hypertensive rat is associated with amelioration of metabolic disturbances but has no effect on hypertension. Physiol Res 2003; 52: 681-688.
12. Sanz-Rosa D, Oubina MP, Cediel E, et al. Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am J Physiol Heart Circ Physiol 2005; 288: 111-115.
13. Zilka N, Filipcik P, Koson P, et al. Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett 2006; 580: 3582-3588.
14. Zilka N, Stozicka Z, Kovac A, et al. Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy. J Neuroimmunol 2009; 209: 16-25.
15. Guo Z, Fratiglioni L, Zhu L, et al. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol 1999; 56: 991-996.
16. Murray MD, Lane KA, Gao S, et al. Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. Arch Intern Med 2002; 162: 2090-2096.
17. Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ.340: b5465.
18. Wang J, Ho L, Chen L, et al. Valsartan lowers brain betaamyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117: 3393-3402.
19. Hajjar I, Brown L, Mack WJ, et al. Impact of angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol 2012; 10: 1-7.
20. Gohlke P, Weiss S, Jansen A, et al. AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther 2001; 298: 62-70.
21. Maillard MP, Perregaux C, Centeno C, et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 2002; 302: 1089-1095.
22. Wienen W, Schierok HJ. Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats. J Renin Angiotensin Aldosterone Syst 2001; 2: 123-128.
23. Kumai Y, Ooboshi H, Ago T, et al. Protective effects of angiotensin II type 1 receptor blocker on cerebral circulation independent of blood pressure. Exp Neurol 2008; 210: 441-448.
24. Zhong JC, Ye JY, Jin HY, et al. Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul Pept 2011; 166: 90-97.
25. Li YQ, Ji H, Zhang YH, et al. Metabolic effects of telmisartan in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 2006; 373: 264-270.
26. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
27. Chiang KH, Liou JY, Shyu KG, et al. Hypertension due to co-existing paraganglioma and unilateral adrenal cortical hyperplasia. J Formos Med Assoc 2007; 106: 1043-1047.
28. Poon IO. Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. Pharmacotherapy 2008; 28: 366-375.
29. Pelisch N, Hosomi N, Ueno M, et al. Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats. Am J Hypertens 2011; 24: 362-368.
30. Ueno M, Sakamoto H, Liao YJ, et al. Blood-brain barrier disruption in the hypothalamus of young adult spontaneously hypertensive rats. Histochem Cell Biol 2004; 122: 131-137.
31. Kishi T, Hirooka Y, Sunagawa K. Telmisartan protects against cognitive decline via up-regulation of brainderived neurotrophic factor/tropomyosin-related kinaseB in hippocampus of hypertensive rats. J Cardiol 2012; 60: 489-494.
32. Gyure KA, Durham R, Stewart WF, et al. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 2001; 125: 489-492.
33. Mori C, Spooner ET, Wisniewsk KE, et al. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 2002; 9: 88-102.
34. Kehoe PG, Wilcock GK. Is inhibition of the reninangiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 2007; 6: 373-378.
35. Saxby BK, Harrington F, Wesnes KA, et al. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology 2008; 70: 1858-1866.
36. Tota S, Kamat PK, Awasthi H, et al. Candesartan improves memory decline in mice: involvement of AT1 receptors in memory deficit induced by intracerebral streptozotocin. Behav Brain Res 2009; 199: 235-240.
37. Haraguchi T, Iwasaki K, Takasaki K, et al. Telmisartan, a partial agonist of peroxisome proliferator-activated receptor gamma, improves impairment of spatial memory and hippocampal apoptosis in rats treated with repeated cerebral ischemia. Brain Res 2010; 1353: 125-132.
38. Ittner LM, Gotz J. Amyloid-b and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011; 12: 65-72.
39. Grunfeld S, Hamilton CA, Mesaros S, et al. Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension 1995; 26: 854-857.
40. Suzuki H, Swei A, Zweifach BW, et al. In vivo evidence for microvascular oxidative stress in spontaneously hypertensive rats. Hydroethidine microfluorography. Hypertension 1995; 25: 1083-1089.
41. Stozicka Z, Zilka N, Novak P, et al. Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease. J Neuroinflammation 2010; 7: 64.
42. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005; 11: RA194-RA205.
43. Jung KH, Chu K, Lee ST, et al. Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther 2007; 322: 1051-1058.
44. Dai Q, Xu M, Yao M, et al. Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br J Pharmacol 2007; 152: 1042-1048.
45. Kurata T, Miyazaki K, Kozuki M, et al. Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease. Neurol Res 2012; 34: 601-610.